Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Rhea-AI Summary

Abbott's i-STAT TBI cartridge receives FDA clearance for whole blood use, enabling rapid assessment of mild traumatic brain injury at patient's bedside. Test provides lab-quality results in 15 minutes, expanding testing capabilities beyond traditional healthcare settings.

Insights

Medical Research Analyst

The FDA clearance of Abbott's i-STAT TBI cartridge for use with whole blood represents a significant advancement in the field of traumatic brain injury (TBI) assessment. This clearance translates to an accelerated and more accessible diagnostic process for mild traumatic brain injuries, which could potentially reduce the number of unnecessary CT scans. Reducing reliance on CT scans not only lowers radiation exposure to patients but also alleviates the burden on medical imaging facilities.

From a medical research perspective, the use of biomarkers such as UCH-L1 and GFAP to assess brain injuries is a growing area of interest. The ability to measure these biomarkers quickly at the point of care could lead to a paradigm shift in how emergency departments and other healthcare settings manage suspected TBIs. This tool's potential to improve patient outcomes by enabling faster decision-making could be significant, particularly in sports medicine and military applications where rapid assessment is critical.

Healthcare Economist

The economic implications of this FDA clearance are multifaceted. For healthcare providers, the availability of a rapid, bedside concussion assessment tool could result in operational efficiencies and cost savings. By potentially reducing the number of CT scans, hospitals and clinics might see decreased costs associated with imaging and an increased throughput of patients. This could lead to a more cost-effective management of suspected TBI cases.

From a broader economic standpoint, the ability to quickly rule out the need for further examination could lessen the societal costs associated with TBIs, such as lost productivity and long-term healthcare expenses. However, it is essential to balance these potential benefits against the cost of the i-STAT TBI cartridges and the Alinity systems, as well as the training required for healthcare professionals to operate the new technology effectively.

Market Research Analyst

In the context of market dynamics, Abbott's advancement in TBI assessment technology may position the company as a leader in the point-of-care diagnostics market. The demand for rapid diagnostic tests is growing and Abbott's ability to meet this demand can affect its market share positively. This FDA clearance could also stimulate competition as other companies strive to develop similar technologies.

It is important to monitor how this product is adopted in various healthcare settings and the impact on Abbott's financial performance. The test's reception in urgent care clinics, emergency departments and potentially in sports and military applications could serve as indicators of the product's success and its influence on Abbott's stock performance. Analysts should track sales data, adoption rates and customer feedback to gauge the market's response to this innovation.

• The test, run on Abbott's portable i-STAT^® Alinity^® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), or concussion
• The test produces lab-quality results in 15 minutes
• Clinicians are now able to get a result at the patient's bedside, making the test accessible at urgent care clinics and other healthcare settings outside the hospital emergency room
• The test can be used to help evaluate patients up to 24 hours after injury

ABBOTT PARK, Ill., April 1, 2024 /PRNewswire/ -- Abbott's i-STAT TBI cartridge has received clearance from the U.S. Food and Drug Administration (FDA) to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests to help with the assessment of TBI were only cleared for use with plasma or serum, requiring samples to be sent to a lab for processing and testing.

This new clearance will enable testing to be performed in an array of new healthcare settings beyond hospital emergency departments including urgent care clinics with a certificate to perform moderate complexity tests. This is an important step toward a future where testing could be done outside traditional healthcare settings, such as on the sidelines of sporting events.

The whole blood test on a portable instrument helps clinicians evaluate patients 18 years of age and older who present with suspected mild traumatic brain injury or mTBI, commonly known as concussion. Test results can help rule out the need for a CT scan of the head and assist in determining the best next steps for patient care. The ability to perform the test with a whole blood sample means testing can take place at healthcare settings without a lab which helps to accelerate the evaluation of head traumas.

With this clearance, the i-STAT TBI test can be used to help evaluate patients up to 24 hours after injury, an important advancement since those injured often wait before seeking care.

Nearly 5 million people go to the emergency department for a TBI in the U.S. each year, but more than half of people who suspect they have a concussion never get it checked.

For decades, standard TBI assessment has remained the same, with doctors leveraging the Glasgow Coma Scale, a subjective doctor assessment, and CT scans to detect brain tissue damage or lesions.

"Emergency departments can be a busy place. It's important to be able to triage patients quickly," said Geoffrey Manley, M.D., PhD, Chief of Neurosurgery at Zuckerberg San Francisco General Hospital, Professor of Neurosurgery at the University of California San Francisco and contact principal investigator for the TRACK-TBI Network. "Historically, that process for suspected concussions was largely subjective. With the help of this whole blood test, we can quickly and objectively determine whether or not a patient needs a CT scan or additional evaluation, right at the point of care. It's an incredibly helpful tool that advances the treatment of traumatic brain injury." 

How the test works 
The i-STAT TBI cartridge with the i-STAT Alinity System requires a small venous blood sample, which is applied to the test cartridge. The cartridge is then inserted into the portable i-STAT Alinity instrument. The test measures two biomarkers from the brain that may be released into the bloodstream, indicating a possible brain injury. Testing for these two biomarkers – ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) – in the aftermath of an injury can provide clinicians with essential information about a patient's condition and can help healthcare providers decide an appropriate treatment plan.

"Clinicians have needed an objective way to assess patients with concussions," said Beth McQuiston, M.D., medical director in Abbott's diagnostics business. "When you look at all the other diseases, or other organs in the body, they all have blood tests to help assess what's happening. Now, we have a whole blood test that can help assess the brain right at the patient's bedside – expanding access to more health providers and therefore patients."

The newly cleared test expands Abbott's TBI test offerings, which includes the i-STAT TBI Plasma test and the ARCHITECT^® and Alinity i lab test (serum and plasma), which were all cleared previously.

The ability to use whole blood to help assess TBI is an important step in Abbott's vision to make its tests available in all settings where people seek care for head injuries. Abbott is engaged in ongoing research and planning that may, in the future, allow the test to be used in non-healthcare settings and with a broader population including teens and pediatrics.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and Youtube.

The i-STAT TBI blood test was developed in collaboration with the U.S. Department of Defense U.S. Army Medical Research and Development Command's (USAMRDC) U.S. Army Medical Materiel Development Activity (USAMMDA). The USAMRDC has been dedicated to developing a solution for the objective detection and evaluation of TBI for more than two decades and has played a critical role in developing the TBI test on Abbott's i-STAT Alinity platform.

The Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) research team was the first to demonstrate how this TBI blood test can be used for the benefit of TBI patients in clinical care.

View original content:https://www.prnewswire.com/news-releases/abbott-receives-fda-clearance-for-whole-blood-rapid-test-to-help-with-assessment-of-concussion-at-the-patients-bedside-302104458.html

SOURCE Abbott

FAQ

What is the significance of Abbott's i-STAT TBI cartridge receiving FDA clearance for whole blood use?

The clearance allows doctors to assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes, facilitating rapid evaluation and decision-making.

How does the whole blood test on Abbott's i-STAT Alinity instrument help clinicians?

The test helps evaluate patients with suspected mild traumatic brain injury, providing crucial information to rule out the need for a CT scan and determine the best course of patient care.

Why is the ability to perform the test with a whole blood sample significant?

Testing with whole blood samples enables healthcare settings without a lab to conduct assessments, accelerating the evaluation of head traumas and improving patient outcomes.

What impact does the FDA clearance have on the evaluation timeline for patients with suspected concussion?

The clearance allows testing to be done up to 24 hours after injury, reducing delays in assessment and ensuring timely care for individuals with head traumas.

How does the i-STAT TBI test advance the treatment of traumatic brain injury?

The test provides objective information to quickly determine the need for a CT scan or further evaluation, enhancing the triaging process in emergency departments and improving patient management.